S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
OPK · OPKO Health, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$1.60
-0.06
(-3.90%)
● At close: October 21 at 4:00:00 PM EDT
$1.61
+0.01
(+0.62%)
Overnight:
10:41:36 PM EDT
DAY'S RANGE
$1.60
$1.59
$1.66
52-WEEK RANGE
$1.60
$0.98
$1.77
What's happening
- OPK is down 3.90% today, trading at $1.60. — Live quote
- Volume today (100,464) is well below its 3-month average of 3,894,520. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.01 actual vs. $-0.08 estimated (+87.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
OPK
+31.75%
vs S&P 500
+18.97%
1-YEAR RETURN
OPK
+8.50%
vs S&P 500
-6.06%
6-MONTH RETURN
OPK
+37.19%
3-MONTH RETURN
OPK
+37.19%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.01
Est. $-0.08
BEAT +87.6%
2026-04-26 (Q1 2026)
$-0.07
Est. $-0.07
BEAT +1.0%
2026-01-26 (Q4 2025)
$-0.04
Est. $-0.07
BEAT +42.3%
2025-10-26 (Q3 2025)
$0.03
Est. $-0.05
BEAT +165.9%
Valuation Measures & Ratios
Enterprise Value4$1.28B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1.35
Price / Book70.96
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-23.93%
Operating Margin-16.52%
Return on Equity (ROE8)-5.88%
Return on Assets (ROA9)-3.83%
Avg Volume (3M)3,894,520
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| Market cap | $1.27B | $897.2M | $976.8M | $1.12B | $1.02B |
| P/E | -17.43 | -4.21 | -4.33 | -6.20 | -5.78 |
| Price/Sales | 2.16 | 1.54 | 1.61 | 1.74 | 1.54 |
| Price/Book | 1.07 | 0.74 | 0.77 | 0.86 | 0.79 |
| EV/Revenue | 1.65 | 0.98 | 1.02 | 1.11 | 1.15 |
| ROE | -6.16% | -17.68% | -17.80% | -13.82% | -13.66% |
| ROA | -3.98% | -11.47% | -11.68% | -9.04% | -8.98% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short35,560,259
Change from Prior Settlement-1.19%
% of Float—
Days to Cover (Short Ratio)14.94
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +8.5%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -0.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -23.9%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OPK
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163.6M | $124.2M | $148.5M | $151.7M | $156.8M | $150.0M | $183.6M | $173.6M |
| Gross profit | $80.0M | $45.8M | — | $49.9M | $49.4M | $42.6M | — | $40.1M |
| Operating income | -$7.0M | -$51.0M | — | $48.1M | -$60.0M | -$67.2M | — | -$67.2M |
| Net income | -$8.4M | -$54.8M | -$31.3M | $21.6M | -$148.4M | -$67.6M | $14.0M | $24.9M |
| EPS (diluted) | $-0.01 | $-0.07 | $-0.04 | $0.03 | $-0.19 | $-0.10 | $0.01 | $0.03 |
| EPS (basic) | $-0.01 | $-0.07 | $-0.04 | $0.03 | $-0.19 | $-0.10 | $0.02 | $0.04 |
| Operating margin | -$4 | -$41 | — | $32 | -$38 | -$45 | — | -$39 |
| Net margin | -$5 | -$44 | -$21 | $14 | -$95 | -$45 | $8 | $14 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.83B | $1.86B | $1.93B | $2.00B | $1.97B | $2.13B | $2.20B | $2.26B |
| Total liabilities | $645.3M | $652.2M | $664.0M | $690.0M | $676.1M | $816.7M | $834.8M | $852.7M |
| Stockholders' equity | $1.18B | $1.20B | $1.27B | $1.31B | $1.30B | $1.31B | $1.37B | $1.40B |
| Total current assets | $500.2M | $535.4M | $581.9M | $627.1M | $583.3M | $737.6M | $662.1M | $629.6M |
| Total current liabilities | $149.4M | $148.4M | $146.7M | $169.3M | $171.2M | $295.9M | $193.1M | $211.7M |
| Cash & equivalents | $300.8M | $331.9M | $364.4M | $412.0M | $267.3M | $428.8M | $426.6M | $400.1M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $81.9M | $79.6M | $90.3M | $94.6M | $99.4M | $96.2M | $118.0M | $106.6M |
| Inventory | $61.9M | $64.4M | $65.8M | $65.0M | $66.3M | $64.0M | $56.8M | $59.4M |
| Other current assets | $9.8M | $9.8M | $8.2M | $7.7M | $8.5M | $10.8M | $10.7M | $9.3M |
| Marketable securities (non-current) | $40.2M | $10.5M | $14.2M | $13.4M | $13.0M | $12.8M | $54.6M | $100.6M |
| Property, plant & equipment | $71.5M | $72.6M | $73.9M | $75.0M | $74.9M | $71.2M | $70.1M | — |
| Goodwill | $481.5M | $482.3M | $484.3M | $484.0M | $484.2M | $476.7M | $529.3M | $535.9M |
| Intangible assets | $477.6M | $496.4M | $516.3M | $535.4M | $556.0M | $568.5M | $616.6M | $641.4M |
| Other non-current assets | $19.5M | $18.9M | $19.5M | $19.9M | $19.9M | $18.8M | $18.5M | $18.5M |
| Accounts payable | $50.0M | $44.2M | $41.1M | $50.8M | $56.7M | $59.4M | $47.1M | $62.7M |
| Accrued liabilities | $77.8M | $83.5M | $84.4M | $95.6M | $90.6M | $113.2M | $118.4M | $122.8M |
| Deferred revenue (current) | — | — | — | — | — | — | $6.0K | — |
| Short-term debt | $912.0K | $1.5M | $1.7M | $1.5M | $1.5M | $1.4M | $437.2M | $1.5M |
| Long-term debt | $1.8M | $2.0M | $2.3M | $2.5M | $2.8M | $2.8M | $3.0M | $3.5M |
| Other non-current liabilities | $17.0M | $19.6M | $22.8M | $25.2M | $27.8M | $30.0M | $32.8M | $36.5M |
| Common stock & paid-in capital | $7.8M | $7.8M | $7.9M | $8.0M | $8.1M | $7.0M | $7.0M | $7.1M |
| Retained earnings | -$2.35B | -$2.35B | -$2.29B | -$2.26B | -$2.28B | -$2.13B | -$2.07B | -$2.08B |
| Accumulated other comprehensive income (loss) | -$28.4M | -$27.5M | -$21.0M | -$25.5M | -$24.7M | -$45.0M | -$56.1M | -$39.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.5M | -$19.3M | -$25.9M | -$34.6M | -$83.4M | -$34.6M | -$44.4M | -$77.1M |
| Investing cash flow | $15.5M | -$1.8M | -$2.0M | $194.6M | -$2.8M | $40.5M | $116.0M | $247.8M |
| Financing cash flow | -$13.0M | -$5.2M | -$18.3M | -$16.2M | -$79.5M | -$4.0M | -$40.5M | $206.1M |
| Depreciation & amortization | $22.4M | $22.2M | $68.1M | $22.7M | $23.0M | $23.5M | $72.4M | $24.2M |
| Share-based compensation | $2.2M | $2.7M | $8.1M | $3.0M | $2.2M | $2.6M | $8.5M | $2.8M |
| Deferred income taxes | -$6.3M | -$7.9M | -$10.1M | $18.3M | -$15.7M | -$7.4M | $7.0M | $12.2M |
| Change in accounts receivable | $2.4M | -$9.5M | -$6.7M | -$4.4M | $3.8M | -$22.9M | $15.9M | -$327.0K |
| Change in inventory | -$2.8M | -$191.0K | -$1.2M | -$624.0K | $478.0K | $5.4M | $2.2M | -$4.7M |
| Change in accounts payable | $5.4M | $3.5M | -$17.1M | -$5.2M | -$3.4M | $11.5M | -$14.1M | -$20.2M |
| Purchases of investments | — | — | — | $0 | — | — | — | $1.5M |
| Other investing activities | — | — | — | — | — | — | — | — |
| Share repurchases | $13.0M | $4.8M | $13.5M | $15.3M | $18.3M | $0 | $16.5M | $23.8M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1.00B | $1.77B |
| Gross profit | $205.9M | $218.5M | $318.1M | $288.2M | — |
| Operating income | -$117.4M | -$152.1M | -$157.0M | -$226.3M | $18.8M |
| Net income | -$225.7M | -$53.2M | -$188.9M | -$328.4M | -$30.1M |
| EPS (diluted) | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 |
| EPS (basic) | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 |
| Operating margin | -$19 | -$21 | -$18 | -$23 | $1 |
| Net margin | -$37 | -$7 | -$22 | -$33 | -$2 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 |
|---|---|---|---|---|---|
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | — |
| Total liabilities | $664.0M | $834.8M | $622.5M | $605.6M | — |
| Stockholders' equity | $1.27B | $1.37B | $1.39B | $1.56B | — |
| Total current assets | $581.9M | $662.1M | $309.5M | $394.5M | — |
| Total current liabilities | $146.7M | $193.1M | $200.1M | $213.5M | — |
| Cash & equivalents | $364.4M | $426.6M | $95.9M | $153.2M | — |
| Accounts receivable | $90.3M | $118.0M | $123.4M | $127.3M | — |
| Inventory | $65.8M | $56.8M | $65.7M | $74.1M | — |
| Other current assets | $8.2M | $10.7M | $7.7M | $6.3M | — |
| Marketable securities (non-current) | $14.2M | $54.6M | $16.1M | $28.1M | — |
| Property, plant & equipment | $73.9M | $70.1M | $75.4M | $82.9M | — |
| Goodwill | $484.3M | $529.3M | $598.3M | $595.9M | $710.4M |
| Intangible assets | $516.3M | $616.6M | $740.3M | $823.5M | — |
| Other non-current assets | $19.5M | $18.5M | $9.1M | $8.7M | — |
| Accounts payable | $41.1M | $47.1M | $69.7M | $67.0M | — |
| Accrued liabilities | $84.4M | $118.4M | $90.1M | $98.3M | — |
| Deferred revenue (current) | — | $6.0K | $7.0K | $0 | — |
| Short-term debt | $344.0M | $437.2M | $2.0M | $1.7M | — |
| Long-term debt | $2.3M | $3.0M | $7.7M | $9.3M | — |
| Other non-current liabilities | $22.8M | $32.8M | $27.2M | $27.4M | — |
| Common stock & paid-in capital | $7.9M | $7.0M | $7.8M | $7.8M | — |
| Retained earnings | -$2.29B | -$2.07B | -$2.01B | -$1.82B | — |
| Accumulated other comprehensive income (loss) | -$21.0M | -$56.1M | -$38.0M | -$43.3M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$178.5M | -$183.5M | -$28.2M | -$95.2M | $38.3M |
| Investing cash flow | $230.3M | $352.2M | -$18.2M | $91.0M | $35.9M |
| Financing cash flow | -$118.1M | $184.2M | -$11.3M | $23.0M | -$10.3M |
| Depreciation & amortization | $91.6M | $98.2M | $105.3M | $108.7M | $78.7M |
| Share-based compensation | $10.7M | $11.0M | $11.4M | $18.5M | $13.6M |
| Deferred income taxes | -$15.0M | $14.7M | $146.0K | -$74.4M | $10.2M |
| Change in accounts receivable | -$30.2M | $220.0K | -$3.4M | -$128.6M | -$5.2M |
| Change in inventory | $4.1M | -$4.2M | -$15.2M | -$13.7M | -$30.7M |
| Change in accounts payable | -$14.2M | -$20.7M | $2.8M | -$9.4M | -$10.8M |
| Purchases of investments | — | — | — | — | — |
| Other investing activities | — | — | — | — | — |
| Share repurchases | $47.0M | $90.2M | $0 | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OPK as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-08-08 to 2026-07-24
Recent transactions
- Most recent: Logal Adam (Sr. Vice President, CFO) — Tax withholding of 53,266 shares on 2026-07-24.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Logal Adam | Sr. Vice President, CFO | Tax withholding | 2026-07-24 | 53,266 |
| Rubin Steven D | Executive VP-Administration | Tax withholding | 2026-07-24 | 53,266 |
| PAGANELLI JOHN A | Reporting person | Open market purchase | 2026-03-20 | 10,000 |
| FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 2025-11-21 | 102,371 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-24 | Logal Adam | Sr. Vice President, CFO | Tax withholding | 53,266 | $1.22 |
| 2026-07-24 | Rubin Steven D | Executive VP-Administration | Tax withholding | 53,266 | $1.22 |
| 2026-03-20 | PAGANELLI JOHN A | Reporting person | Open market purchase | 10,000 | $1.14 |
| 2025-11-21 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 102,371 | $1.30 |
| 2025-11-21 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 3,894 | $1.32 |
| 2025-11-21 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 89,375 | $1.32 |
| 2025-11-21 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 191,490 | $1.33 |
| 2025-11-21 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 192,870 | $1.33 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 119,129 | $1.32 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 47,105 | $1.32 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 211,948 | $1.33 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 161,818 | $1.33 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 24,579 | $1.34 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 1,757 | $1.34 |
| 2025-11-20 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 13,664 | $1.35 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 36,325 | $1.28 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 58,160 | $1.28 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 300 | $1.29 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 21,236 | $1.29 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 30,082 | $1.30 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 12,993 | $1.30 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 66,504 | $1.31 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 198,904 | $1.31 |
| 2025-11-19 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 155,496 | $1.32 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 410 | $1.25 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 49,590 | $1.25 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 66,635 | $1.25 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Grant / award | 46,700 | $1.26 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 15,000 | $1.26 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 1,772 | $1.27 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 212,608 | $1.27 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 69,728 | $1.28 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 428 | $1.28 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 83,556 | $1.28 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 1 | $1.29 |
| 2025-11-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 33,572 | $1.29 |
| 2025-10-31 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 150,000 | $1.42 |
| 2025-08-18 | FROST PHILLIP MD ET AL | CEO & Chairman | Gift | 440,000 | $0.00 |
| 2025-08-08 | FROST PHILLIP MD ET AL | CEO & Chairman | Open market purchase | 675,000 | $1.32 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:07 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-10-02 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-24 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-24 | View on SEC.gov → |
| 2026-07-27 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
Recent news
Headlines about OPK (OPKO Health, Inc.). Links open the publisher — we don’t host full articles.
-
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy
Yahoo · 2026-10-21 -
H.C. Wainwright keeps USD 3.00 target for OPKO Health stock
AD HOC NEWS · 2026-10-20 -
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Benzinga · 2026-10-20 -
OPK Nov 2026 2.500 call (OPK261120C00002500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
OPKO Health, Inc. (OPK) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides
Yahoo · 2026-10-17 -
Barrington sets USD 2.25 target for OPKO Health stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
Is OPKO Health (OPK) Pricing In Too Much For Sales?
Yahoo · 2026-10-17
No headlines in this category right now — try “All”.